大分割剂量提升对比常规分割放疗治疗中高危局限期前列腺癌:HYPRO试验长期结果
HYPRO试验是一项多中心随机III期优效性研究,比较剂量提升大分割放疗(HF)与常规分割放疗(CF)治疗中高危局限期前列腺癌,旨在证明HF毒性等效。
要点
- HF方案(64.4 Gy/19次)对比CF(78.0 Gy/39次),基于α/β≈1.5 Gy折算等效剂量为90.4 Gy vs 78.0 Gy。
核心结论
- 剂量提升大分割放疗对比常规分割放疗,未显著改善10年无复发生存,总生存的有利差异在多因素分析中未保持统计学显著。
研究设计与样本
- 多中心、随机、III期优效性试验,1:1随机分配中高危T1b-T4NX-N0MX-M0局限期前列腺癌患者。
- HF组接受64.4 Gy/19次(3.4 Gy/次,每周3次),CF组接受78.0 Gy/39次(2 Gy/次,每周5次)。
- 共820例患者随机,804例纳入本次评估,HF组407例,CF组397例。
主要发现
- 多因素分析中总生存差异未保持统计学显著。
关键数值与推荐
- HF方案基于前列腺癌α/β≈1.5 Gy折算,2 Gy分次等效总剂量为90.4 Gy,CF为78.0 Gy。
临床怎么用
- 对于中高危局限期前列腺癌,剂量提升大分割放疗可作为常规分割的替代选择,但长期生存获益未达统计学显著。
- 需结合既往急性和晚期毒性非劣效性未确立的结果,个体化权衡大分割放疗的获益与风险。
局限性
- 总生存差异在多因素分析中未保持统计学显著,需考虑混杂因素影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The HYpofractionated irradiation for PROstate cancer trial was a multicenter, randomized, phase 3, superiority trial comparing dose escalated hypofractionation (HF) with conventional fractionation (CF) for the treatment of localized intermediate- and high-risk prostate cancer. This trial aimed to demonstrate equivalent toxicity of HF. In prior publications, noninferiority of acute and late toxicity could not be established. Here, we report the long-term survival outcomes. METHODS AND MATERIALS: We randomly assigned patients (1:1) with intermediate- to high-risk T1b-T4NX-N0MX-M0 localized prostate cancer to receive either HF (64.4 Gy in 19 fractions of 3.4 Gy, 3 fractions per week) or CF (78.0 Gy in 39 fractions of 2 Gy, 5 fractions per week) radiation therapy. The HF schedule was a dose escalation compared with CF, based on a α/β ratio of prostate cancer of ∼1.5 Gy, the equivalent total dose in fractions of 2 Gy is 90.4 Gy for HF versus 78.0 Gy for CF. The primary endpoint of this paper was relapse-free survival at 10 years and secondary outcome was overall survival. RESULTS: Of the 820 patients, 804 were included in the current evaluation, 407 patients received HF and 397 CF radiation therapy. The 10-year relapse-free survival was 64.5% (95% CI, 58.6-69.7) in the HF arm compared with 60.1% (95% CI, 53.9-65.8) in the CF arm (hazard ratio, 0.89; 95% CI, 0.69-1.14; P = .35). The 10-year overall survival in the HF arm was 69.2% (95% CI, 64.1-73.7) versus 61.2% (95% CI, 55.7-66.2) in the CF arm (hazard ratio, 0.82; 95% CI, 0.65-1.05; P = .11). CONCLUSIONS: In the updated findings, we could not demonstrate a statistically significant improvement in 10-year relapse-free survival following dose escalated HF compared with CF. Although patients in the HF arm showed a favorable 10-year overall survival, this difference did not remain statistically significant in the multivariable analysis.
引用
- Wiersma RG, de Vries KC, Heemsbergen WD, et al. Hypofractionated Dose Escalation Versus Conventionally Fractionated Radiation Therapy for Patients With Intermediate- and High-Risk Localized Prostate Cancer: Long-Term Results of the HYPRO Trial. Int J Radiat Oncol Biol Phys. 2025. PMID: 41106690. doi:10.1016/j.ijrobp.2025.09.067
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。